drugset / Trial / NCT00724802

Oral Glyceryl Triacetate (GTA) in Newborns With Canavan

NCT00724802

Unknown 1 enrolled Shaare Zedek Medical Center
NaSingle-groupOpen-labelTreatment

Summary

Canavan disease is caused by Aspartoacylase deficiency. There is no treatment for the disease, but there is a food additive that includes acetate . We suggest an early treatment with acetate and a neurologic evaluation, including MRI, after 4 months of treatment. In any case the treatment will be stopped at the age of 22 months, when myelinization is ended.

Timeline

Start
2008-03
Primary completion
2008-08
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject TRIACETIN Small molecule 5 g/kg Oral

Indications